REFERENCES

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.

2. Donato F, Tagger A, Gelatti U, Parrinello G, Boffettta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infection in men and women. Am J Epidemiol 2002;155:323-31.

3. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-2.

4. Yang WS, Va P, Bray F, Gao S, Gao J, Li HL, Xiang YB. The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies. PLoS One 2011;6:e27326.

5. Evans RW, Littler TR, Pemberton HS. Glycogen storage in the liver in diabetes mellitus. J Clin Pathol 1955;8:110-3.

6. Stone BG, Van Thiel DH. Diabetes mellitus and the liver. Semin Liver Dis 1985;5:8-28.

7. Bannasch P. The cytoplasm of hepatocytes during carcinogenesis. Electron and light microscopical investigations of the nitrosomorpholine-intoxicated rat liver. Rec Res Cancer Res 1968;19:1-100.

8. Dombrowski F, Bannasch P, Pfeifer U. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats. Am J Pathol 1997;150:1071-87.

9. Bannasch P, Khoshkhou NI, Hacker HJ, Radaeva S, Mrozek M, Zillmann U, Kopp-Schneider A, Haberkorn U, Elgas M, Tolle T, Roggendorf M, Toshkov I. Synergistic hepatocarcinogenic effect of hepadnaviral infection and dietary aflatoxin B1 in woodchucks. Cancer Res 1995;55:3318-30.

10. Altmann HW. Hepatic neoformations. Pathol Res Pract 1994;190:513-77.

11. Su Q, Benner A, Hofmann WJ, Otto G, Pichlmayr R, Bannasch P. Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchows Arch 1997;431:391-406.

12. Buchanan TF, Huvos AG. Clear-cell carcinoma of the liver. A clinicopathologic study of 13 patients. Am J Clin Pathol 1974;61:529-39.

13. Shi Y, Wu H, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int 2012;32:231-40.

14. Bannasch P. Glycogenotic hepatocellular carcinoma with glycogen-ground-glass hepatocytes: a heuristically highly relevant phenotype. World J Gastroenterol 2012;18:6701-8.

15. Ribback S, Calvisi DF, Cigliano A, Sailer V, Peters M, Rausch J, Heidecke CD, Birth M, Dombrowski F. Molecular and metabolic changes in human clear cell foci resemble the alterations occurring in rat hepatocarcinogenesis. J Hepatol 2013;58:1147-56.

16. Teng CF, Hsieh WC, Wu HC, Lin YJ, Tsai HW, Huang W, Su IJ. Hepatitis B virus pre-S2 mutant induces aerobic glycolysis through mammalian target of rapamycin signal cascade. PLoS One 2015;10:e0122373.

17. Bannach P, Klimek F, Mayer D. Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone. J Bioenerg Biomembr 1997;29:303-13.

18. Klimek F, Bannasch P. Isoenzyme shift from glucokinase to hexokinase is not an early but a late event in hepatocarcinogenesis. Carcinogenesis 1993;14:1857-61.

19. Yasuda S, Arii S, Mori A, Isobe N, Yang W, Oe H, Fujimoto A, Yonenaga Y, Sakashita H, Imamura M. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. J Hepatol 2004;40:117-23.

20. Guzman G, Chennuri R, Chan A, Rea B, Quintana A, Patel R, Xu PZ, Xie H, Hay N. Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Dig Dis Sci 2015;60:420-6.